A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Completed
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/15/2025
Locations: Hightower Clinical Trial Services, Oklahoma City, Oklahoma
Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: RAO Research LLC, Oklahoma City, Oklahoma +1 locations
Conditions: Psoriatic Arthritis, Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity
Active Not Recruiting
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Lynn Health Science Institute, Oklahoma City, Oklahoma
Conditions: Obesity
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
Completed
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
02/21/2025
Locations: Lynn Health Science Institute, Oklahoma City, Oklahoma
Conditions: Obesity